Daiichi Sankyo is investing approximately $1 billion into its manufacturing facility in Pfaffenhofen, Germany to boost ADC production capacity
The company plans total global ADC manufacturing investments of $1.9 billion across facilities in Germany, Japan, the U.S., and China
ADC drugs Enhertu and Datroway together contributed ¥538.4 billion (approximately $3.4 billion) in revenue, accounting for 35.1% of total company revenue
By 2029, the worldwide ADC therapy market in oncology is expected to exceed $36 billion, with Daiichi Sankyo forecasted to generate nearly $11 billion in sales
The company aims to have at least five ADCs approved across more than 30 tumor types by 2030, treating approximately 400,000 patients
Building construction at the German facility is expected to be completed by end of 2026 and will create at least 350 new jobs by 2030
Daiichi Sankyo terminated internal development of DS-9606, its next-generation ADC candidate targeting CLDN6